Advisory committees cannot support public trust in FDA decisions if the agency uses them inconsistently. Simple reforms could improve accountability, transparency, and trust.
Funding and Disclosures
Disclosure forms provided by the authors are available at NEJM.org.
This article was published on August 20, 2022, at NEJM.org.
Print Subscriber? Activate your online access.